Paclitaxel ± Cixutumumab as Second-Line Treatment for Metastatic Esophageal or Gastroesophageal Junction Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
Oncologist 2023 Apr 27;[EPub Ahead of Print], S Stockton, P Catalano, SJ Cohen, BA Burtness, EP Mitchell, E Dotan, SJ Lubner, P Kumar, MF Mulcahy, GA Fisher, TL Crandall, A BensonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.